SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-20-143581
Filing Date
2020-05-15
Accepted
2020-05-15 11:07:03
Documents
1
Group Members
SUMITOMO DAINIPPON PHARMA CO., LTD.SUMITOVANT BIOPHARMA LTD.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 TO SCHEDULE 13D d813010dsc13da.htm SC 13D/A 71218
  Complete submission text file 0001193125-20-143581.txt   72864
Mailing Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB
Business Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB 44 207-400-3351
Myovant Sciences Ltd. (Subject) CIK: 0001679082 (see all company filings)

IRS No.: 000000000 | State of Incorp.: CA | Fiscal Year End: 0331
Type: SC 13D/A | Act: 34 | File No.: 005-89732 | Film No.: 20882056
SIC: 2834 Pharmaceutical Preparations

Mailing Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Business Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 813-5543-5142
Sumitomo Chemical Co., Ltd. (Filed by) CIK: 0001798550 (see all company filings)

IRS No.: 980339148 | State of Incorp.: M0 | Fiscal Year End: 0331
Type: SC 13D/A